Literature DB >> 2624919

In vitro differentiation and antigenic changes in human melanoma cell lines.

L Guarini1, M Temponi, G M Edwalds, J R Vita, P B Fisher, S Ferrone.   

Abstract

Malignant transformation of melanocytes may be associated with changes in the expression of HLA antigens and melanoma-associated antigens (MAA). To determine whether these changes reflect the differential expression of HLA antigens and MAA by melanocytes at different stages of differentiation, we have studied the effect of the reversible induction of differentiation by fibroblast interferon (interferon beta) and/or 12-O-tetradecanoyl-phorbol 13-acetate (TPA) on the expression of HLA antigens and MAA by the melanoma cell lines DU-2, FO-1 and HO-1. The three melanoma cell lines differed in their sensitivity to the differentiating and antiproliferative activity of these two compounds and displayed an increased growth suppression and induction of differentiation, when incubated with the combination of TPA and interferon beta. Incubation of the three melanoma cell lines with interferon beta, TPA or their combination resulted in a differential modulation of the expression of membrane-bound high-molecular-mass melanoma-associated antigen, 115-kDa MAA, 100-kDa MAA, intercellular adhesion molecule 1, HLA class I antigens and gene products of the HLA-D region. Each melanoma cell line displayed a unique pattern of antigenic modulation when exposed to the two differentiating agents alone or in combination. No direct relationship was found between the effects of interferon beta and/or TPA on the growth and differentiation of the three melanoma cell lines and the expression of HLA antigens or the MAA evaluated in the present study. These findings argue against a direct role of any of the antigens tested in the reversible induction of human melanoma cell differentiation in the in vitro system.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2624919     DOI: 10.1007/bf01744892

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  11 in total

1.  Regulation of the antigenic phenotype of human melanoma cells by recombinant interferons.

Authors:  P Giacomini; R Gambari; R Barbieri; P Nisticò; R Tecce; S Pestka; K Gustafsson; P G Natali; P B Fisher
Journal:  Anticancer Res       Date:  1986 Sep-Oct       Impact factor: 2.480

2.  Modulation of tumor associated antigen expression and shedding by recombinant human leukocyte and fibroblast interferons.

Authors:  J W Greiner; J Schlom; S Pestka; J A Langer; P Giacomini; M Kusama; S Ferrone; P B Fisher
Journal:  Pharmacol Ther       Date:  1985       Impact factor: 12.310

3.  Increased surface expression and shedding of tumor associated antigens by human breast carcinoma cells treated with recombinant human interferons or phorbol ester tumor promoters.

Authors:  J A Leon; R Mesa-Tejada; M C Gutierrez; A Estabrook; J W Greiner; J Schlom; P B Fisher
Journal:  Anticancer Res       Date:  1989 Nov-Dec       Impact factor: 2.480

4.  A 94,000-dalton glycoprotein expressed by human melanoma and carcinoma cells.

Authors:  K Imai; B S Wilson; A Bigotti; P G Natali; S Ferrone
Journal:  J Natl Cancer Inst       Date:  1982-05       Impact factor: 13.506

5.  Stimulation of differentiated functions in human melanoma cells by tumor-promoting agents and dimethyl sulfoxide.

Authors:  E Huberman; C Heckman; R Langenbach
Journal:  Cancer Res       Date:  1979-07       Impact factor: 12.701

6.  Level of a membrane-bound high-molecular-weight melanoma-associated antigen and a cytoplasmic melanoma-associated antigen in surgically removed tissues and in sera from patients with melanoma.

Authors:  P Giacomini; F Veglia; P Cordiali Fei; T Rehle; P G Natali; S Ferrone
Journal:  Cancer Res       Date:  1984-03       Impact factor: 12.701

7.  Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis.

Authors:  C J Barnstable; W F Bodmer; G Brown; G Galfre; C Milstein; A F Williams; A Ziegler
Journal:  Cell       Date:  1978-05       Impact factor: 41.582

8.  Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo.

Authors:  J W Greiner; F Guadagni; P Noguchi; S Pestka; D Colcher; P B Fisher; J Schlom
Journal:  Science       Date:  1987-02-20       Impact factor: 47.728

9.  Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells.

Authors:  P Giacomini; A Aguzzi; S Pestka; P B Fisher; S Ferrone
Journal:  J Immunol       Date:  1984-09       Impact factor: 5.422

10.  Effects of combined treatment with interferon and mezerein on melanogenesis and growth in human melanoma cells.

Authors:  P B Fisher; D R Prignoli; H Hermo; I B Weinstein; S Pestka
Journal:  J Interferon Res       Date:  1985
View more
  7 in total

1.  Potentiation of growth suppression and modulation of the antigenic phenotype in human melanoma cells by the combination of recombinant human fibroblast and immune interferons.

Authors:  G M Graham; L Guarini; T A Moulton; S Datta; S Ferrone; P Giacomini; R S Kerbel; P B Fisher
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Modulation of the antigenic phenotype of human breast carcinoma cells by modifiers of protein kinase C activity and recombinant human interferons.

Authors:  J A Leon; M C Gutierrez; H Jiang; A Estabrook; S Waxman; P B Fisher
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene.

Authors:  M Maio; M Altomonte; R Tatake; R A Zeff; S Ferrone
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

4.  Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression.

Authors:  C M D'Urso; Z G Wang; Y Cao; R Tatake; R A Zeff; S Ferrone
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

Review 5.  Human polynucleotide phosphorylase (hPNPase(old-35)): an evolutionary conserved gene with an expanding repertoire of RNA degradation functions.

Authors:  S K Das; S K Bhutia; U K Sokhi; R Dash; B Azab; D Sarkar; P B Fisher
Journal:  Oncogene       Date:  2010-12-13       Impact factor: 9.867

Review 6.  mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine.

Authors:  Pankaj Gupta; Zao-zhong Su; Irina V Lebedeva; Devanand Sarkar; Moira Sauane; Luni Emdad; Michael A Bachelor; Steven Grant; David T Curiel; Paul Dent; Paul B Fisher
Journal:  Pharmacol Ther       Date:  2006-02-07       Impact factor: 12.310

7.  Lysosomal-associated transmembrane protein 5 (LAPTM5) is a molecular partner of CD1e.

Authors:  Catherine Angénieux; François Waharte; Alexandre Gidon; François Signorino-Gelo; Virginie Wurtz; Rim Hojeij; Fabienne Proamer; Christian Gachet; Alain Van Dorsselaer; Daniel Hanau; Jean Salamero; Henri de la Salle
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.